Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - European Journal of
CME; Niraparib, Olaparib, bevacizumab, PRIMA trial, PAOLO-1
Inhibidores de PARP en primera línea de cáncer de ovario | PPT
Zejula (niraparib) com resultados positivos como terapêutica de primeira linha | Netfarma
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Efficacy | ZEJULA (niraparib) for HCPs
Predictors of Long-term Progression-Free Survival in Niraparib-Treated Patients in the PRIMA/ENGOT-OV16/GOG-3012 Study
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions | Oncology and Therapy
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial - Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Use of First-Line PARP Inhibitors in Ovarian Cancer | Published in healthbook TIMES Oncology Hematology
Niraparib in Patients With Newly Diagnosed Advanced Ovarian BRCAm Cancer: A Post Hoc Analysis of the PRIMA/ENGOT-OV26/GOG-3012 T
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Pivotal Trials in the Realm of Ovarian Cancer
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
TESARO Pioneers Summit - ppt download
Treatment and Maintenance Therapy in Advanced Ovarian Cancer | VuMedi
PARP Inhibitors. - ppt download
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT‐OV26/GOG‐3012 trial - Mirza - 2023 - Cancer - Wiley Online Library
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer | PPT
